PDE10A and Huntington disease: PDE10A loss may represent a homeostatic adaptation to maintain impaired cyclic nucleotide signaling in HD; nonetheless, PDE10A inhibitors are effective in raising striatal cAMP and cGMP and, consequently, reducing or preventing the emergence of HD neurophysiological deficits in symptomatic and presymptomatic HD models, respectively